0.38Open0.33Pre Close12 Volume29 Open Interest5.00Strike Price472.00Turnover133.84%IV25.87%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier32DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.2266Delta0.1219Gamma15.51Leverage Ratio-0.0114Theta-0.0015Rho-3.51Eff Leverage0.0056Vega
uniQure NV Stock Discussion
I went with the wrong Curi! lol, both are good LT though
$uniQure NV (QURE.US)$
📊⚡️📊
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) announced that the U.S. FDA has granted Orphan Drug Designation to AMT-191, their investigational gene therapy for Fabry disease. This follows the dosing of the first patient in a U.S. multi-center, open-label Phase I/IIa trial in August 2024. AMT-191 is a one-time intravenously administered AAV5-based gene therapy targeting the liver to produce G...
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) has initiated dosing in a Phase I/IIa clinical trial of AMT-191 for Fabry diseasetreatment. The multi-center, open-label trial in the US will assess safety, tolerability, and early efficacy signs in two dose-escalating cohorts. AMT-191 is an AAV5-based gene therapy delivering a galactosidase alpha (GLA) transgene to the live...
No comment yet